With respect to GC, clinical trials have demonstrated antitumor activity with PD‐1/PD‐L1 inhibitors,8 with the milestone clinical trial Checkmate 649 leading to the Food and Drug Administration approval of the PD‐1 inhibitor nivolumab for advanced or metastatic GC.9 The gene discussed is CD274; the disease is gastric cancer.